Research graph
References from Microbiome-targeted antibiotics provide no additional microbiologic or inflammatory benefit during cystic fibrosis pulmonary exacerbations: results from the CFMATTERS trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus
10.1034/j.1399-3003.2000.16d30.x · 2000 · External reference
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations
10.1164/rccm.200812-1845pp · 2009 · External reference
Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment
10.1016/j.jcf.2023.11.010 · 2024 · External reference
The cystic fibrosis lung microbiome
10.1513/annalsats.201306-159mg · 2014 · External reference
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial
10.1183/13993003.02443-2024 · 2025 · External reference
Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers
10.1136/thoraxjnl-2015-207235 · 2016 · External reference
Changes in cystic fibrosis airway microbiota at pulmonary exacerbation
10.1513/annalsats.201211-107oc · 2013 · External reference
Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis
10.1136/thx.2010.137281 · 2011 · External reference
Longitudinal airway microbiota profiling in cystic fibrosis patients enrolled in the CFMATTERS clinical trial
10.1016/s1569-1993(17)30168-6 · 2017 · External reference
Microbial epidemiology of the cystic fibrosis airways: past, present, and future
10.1055/s-0042-1758732 · 2023 · External reference
